Chemical injury induced by the use of topical imiquimod: case report
DOI:
https://doi.org/10.21270/archi.v10i9.5249Keywords:
Pharmaceutical Preparations, Mouth Mucosa, Drug-Related Side Effects and Adverse ReactionsAbstract
Chemical injury consists in damage caused by a substance when it comes into contact with living tissue. Certain drugs can cause this type of lesion in the oral mucosa. Imiquimod (INN) is an example. Erythema, edema, vesicles, erosions, ulcerations and inflammatory reactions are among the adverse effects associated with the use of INN. Nevertheless, since its effects disappear when terminating treatment, INN is still considered an essential drug in the treatment of condyloma acuminata, actinic cheilitis, superficial basal cell carcinoma and molluscum contagiosum. The objective of this work is to report a clinical case of a 34-year-old male patient presenting a symptomatic lesion on the lower and upper lip mucosa; while including a literature review on potential adverse effects when prescribing topical INN 5% for the oral mucosa.
Downloads
References
Gilvetti C, Porter SR, Fedele S. Traumatic chemical oral ulceration: a case report and review of the literature. Br Dent J. 2010;208:297-300.
Dayakar MM, Pai PG, Madhavan SS. “Tetracycline hydrochloride chemical burn” as self-inflicted mucogingival injury: A rare case report. Indian J Dermatol Venereol Lepro. 2012;16:282-85.
Vargo RJ, Warner BM, Potluri A, Prasad JL. Garlic burn of the oral mucosa: A case report and review of self-treatment chemical burns. J Am Dent Assoc. 2017;767-71.
Yuan A, Woo SB. Adverse drug events in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119:35-47.
Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002;27:571-77.
Sapijaszko MJ. Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma. Skin Therapy Lett. 2005;10:2–5.
Barikbin B, Tehranchinia Z, Mozafari N. Treatment of multifocal epithelial hyperplasia with imiquimod. Indian J Dermatol Venereol Leprol. 2014;80:175-77.
Esquivel LP, Fernández LC, Saeb ML, Guerrero BAR, Hernández AS, Méndez SF. Recalcitrant oral squamous cell papilloma lesions in two HIV-infected patients successfully treated with topical imiquimod. J Dermatol Case Rep. 2015;9:19-22.
Chan MYL, Kennedy J, Oakley A. Erythema multiforme triggered by imiquimod 5% cream. Australas J Dermatol. 2017;58:257-58.
Chakrabarty AK, Mraz S, Geisse JK, Anderson NJ. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. J Am Acad Dermatol. 2005;52:35-7.
Kwon HB, Choi YS, Lee JH, Jin SY, Kim BJ, Lee SH et al. Treatment of verrucous carcinoma of the lower lip with topical imiquimod (Aldara®) and debulking therapy. Ann Dermatol. 2011;23:68-71.
Salgueiro AP, de Jesus LH, de Souza IF, Rados PV, Visioli F. Treatment of actinic cheilitis: a systematic review. Clin Oral Investig. 2019;23:2041-53.
Smith KJ, Germain M, Yeager J, Skelton H. Topical 5% imiquimod for the therapy of actinic cheilitis. J Am Acad Dermatol. 2002;47:497-501.
Sotiriou E, Lallas A, Goussi C, Apalla Z, Trigoni A, Chovarda E et al. Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis: a 12‐month follow‐up study. Br J Dermatol. 2011; 165:888-92.
Rinne D, Linhart C, Schöfer H. Lip papillomatosis in immunodeficiency: therapy with imiquimod. Br J Dermatol. 2000;142:196-97.
Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001;44:807-13.
Aldara [package insert]. Loughborough, England: 3M Health Care Limited, 2007.
Allam JP, Erdsach T, Wenghoefer M, Bieber T, Appel TR, Novak N. Successful treatment of extensive human papillomavirus-associated oral leucoplakia with imiquimod. Br J Dermatol. 2008;158:644-46.
Gencoglan G, İnanir İ, Sahin O, Gunduz K. Imiquimod 5% cream for isolated lichen planus of the lip. J Dermatolog Treat. 2011;22:55-9.
Brown RS, Farquharson AA. A topical imiquimod-induced oral mucosal lichenoid reaction: A case report. J Am Dent Assoc. 2014;145:1141-45.
Cantisani C, Lazic T, Richetta AG, Clerico R, Mattozzi C, Calvieri S. Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6:65-9.
Ermertcan AT, Gencoglan G, Eskiizmir G, Temiz P. Microinvasive squamous cell carcinoma arising in discoid lupus erythematosus lesions successfully treated with imiquimod 5% cream. Indian J Dermatol Venereol Leprol. 2013;79:115-17.
McDonald C, Laverick S, Fleming CJ, White SJ. Treatment of actinic cheilitis with imiquimod 5% and a retractor on the lower lip: clinical and histological outcomes in 5 patients. Br J Oral Maxillofac Surg. 2010;48:473-76.
Mullins R, Ansell M, Laverick S. Treatment of oral dysplasia with 5% imiquimod cream: short communication. Br J Oral Maxillofac Surg. 2016;54:1028-29.
Yasar S, Mansur AT, Serdar ZA, Goktay F, Aslan C. Treatment of focal epithelial hyperplasia with topical imiquimod: report of three cases. Pediatr Dermatol. 2009;26:465-68.
Wenzel K, Saka B, Zimmermann R, Gundlach KKH, Barten M, Gross G. Malignant conversion of florid oral and labial papillomatosis during topical immunotherapy with imiquimod. Med Microbiol Immunol. 2003;192:161-64.
Wooten JM. Imiquimod. South Med J. 2005;98:852.
Monteiro JSC, Susana CPSO, Júnior JAR, Gurgel CAS, Souza SCOM, Pinheiro ALB et al. Effects of imiquimod and low-intensity laser (λ660nm) in chemically induced oral carcinomas in hamster buccal pouch mucosa. Lasers Med Sci. 2013;28:1017-24.
Ganjian S, Ourian AJ, Shamtoub G, Wu JJ, Murase JE. Off-label indications for imiquimod. Dermatol Online J. 2009;15:4.
Pancevski G, Pepic S, Idoska S, Tofoski G, Nikolovska S. Topical Imiquimod 5% as a Treatment Option in Solitary Facial Keratoacanthoma. Open Access Maced J Med Sci. 2018;6:531-35.
